These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37038067)

  • 1. Benefits and risks of off-label olanzapine use for symptom management in cancer patients-a case report.
    Dev R; Fortuno ES; Amaram-Davila JS; Haider A; Bruera E
    Ann Palliat Med; 2023 May; 12(3):600-606. PubMed ID: 37038067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study.
    Dev R; Zhong LL; Zarifa A; Albittar AA; Rubin L; Liu S; Yap TA; Dalal S; Hui D; Karp DD; Tsimberidou AM; Piha-Paul SA; Ahnert JR; Fu S; Meric-Bernstam F; Naing A
    Invest New Drugs; 2022 Feb; 40(1):124-133. PubMed ID: 34559346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A modified olanzapine-based anti-emetic regimen for the control of nausea and vomiting in patients receiving weekly cisplatin.
    Mehra N; Christopher V; Dhanushkodi M; Radhakrishnan V; Ganesan TS; Ganesharajah S; Sagar TG; Ganesan P
    Int J Clin Pharm; 2020 Apr; 42(2):662-666. PubMed ID: 32152887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer and chemotherapy-induced nausea and vomiting: a focus on olanzapine.
    Bosnjak SM; Dimitrijevic J; Djordjevic F
    Curr Opin Support Palliat Care; 2016 Jun; 10(2):180-8. PubMed ID: 27028050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolonged extrapyramidal symptoms induced by long-term, intermittent administration of low-dose olanzapine along with metoclopramide for emesis: A case report.
    Sakamoto S; Deguchi Y; Uchida S; Itoh Y; Inoue K
    Neuropsychopharmacol Rep; 2022 Sep; 42(3):380-383. PubMed ID: 35716124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose olanzapine, sedation and chemotherapy-induced nausea and vomiting: a prospective randomized controlled study.
    Mukhopadhyay S; Dutta P; Banerjee S; Bhattacharya B; Biswas S; M Navari R
    Future Oncol; 2021 Jun; 17(16):2041-2056. PubMed ID: 33792376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olanzapine for the Treatment of Advanced Cancer-Related Chronic Nausea and/or Vomiting: A Randomized Pilot Trial.
    Navari RM; Pywell CM; Le-Rademacher JG; White P; Dodge AB; Albany C; Loprinzi CL
    JAMA Oncol; 2020 Jun; 6(6):895-899. PubMed ID: 32379269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy.
    Nakashima K; Murakami H; Yokoyama K; Omori S; Wakuda K; Ono A; Kenmotsu H; Naito T; Nishiyama F; Kikugawa M; Kaneko M; Iwamoto Y; Koizumi S; Mori K; Isobe T; Takahashi T
    Jpn J Clin Oncol; 2017 Sep; 47(9):840-843. PubMed ID: 28633504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide.
    Tienchaiananda P; Nipondhkit W; Maneenil K; Sa-Nguansai S; Payapwattanawong S; Laohavinij S; Maneechavakajorn J
    Ann Palliat Med; 2019 Sep; 8(4):372-380. PubMed ID: 31500422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy.
    Ithimakin S; Theeratrakul P; Laocharoenkiat A; Nimmannit A; Akewanlop C; Soparattanapaisarn N; Techawattanawanna S; Korphaisarn K; Danchaivijitr P
    Support Care Cancer; 2020 Nov; 28(11):5335-5342. PubMed ID: 32128615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiemetic use of olanzapine in patients with advanced cancer: results from an open-label multicenter study.
    Harder S; Groenvold M; Isaksen J; Sigaard J; Frandsen KB; Neergaard MA; Mondrup L; Herrstedt J
    Support Care Cancer; 2019 Aug; 27(8):2849-2856. PubMed ID: 30552594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Olanzapine for Symptom Relief in Cancer Patients.
    Nakagawa N; Suzuki M
    J Pain Palliat Care Pharmacother; 2022 Dec; 36(4):216-222. PubMed ID: 36250742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigating the efficacy and safety of olanzapine prophylaxis for opioid-induced nausea and vomiting (JORTC-PAL20): a study protocol for an open-label, single-arm exploratory study.
    Satomi E; Kobayashi T; Ishikawa A; Arakawa S; Ishiki H; Amano K; Sakiyama N; Ariyoshi K; Kihara K; Oyamada S; Mizushima A
    BMJ Open; 2024 Feb; 14(2):e076575. PubMed ID: 38417963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olanzapine in oncology palliative care.
    Šoukalová Z
    Klin Onkol; 2022; 35(4):276-283. PubMed ID: 35989084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
    Navari RM; Nagy CK; Gray SE
    Support Care Cancer; 2013 Jun; 21(6):1655-63. PubMed ID: 23314603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effects of an anti-emetic tropisetron capsule on QOL of patients with delayed nausea and vomiting induced by cancer chemotherapy. Group for Investigation of QOL Questionnaire for Anti-Emetics used in Cancer Chemotherapy. Joint Research Group for Tropisetron Double-Blind Comparative Study].
    Nukariya N; Kobayashi K; Ishihara Y; Yoneda S; Matsuda T; Yakushiji M; Yamakido M; Fukuoka M; Niitani H; Furue H
    Gan To Kagaku Ryoho; 1996 May; 23(6):757-71. PubMed ID: 8645027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olanzapine (5 mg) plus standard triple antiemetic therapy for the prevention of multiple-day cisplatin hemotherapy-induced nausea and vomiting: a prospective randomized controlled study.
    Gao J; Zhao J; Jiang C; Chen F; Zhao L; Jiang Y; Li H; Wang W; Wu Y; Jin Y; Da L; Liu G; Zhang Y; Li H; Zhang Z; Jin G; Li Q
    Support Care Cancer; 2022 Jul; 30(7):6225-6232. PubMed ID: 35449368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Olanzapine 5 mg versus 10 mg for the Prophylaxis of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving High Emetic Risk Chemotherapy without Neurokinin-1 Receptor Antagonist.
    Sukauichai S; Ketkaew C; Othaganont N; Pichaya P; Promsuwan P
    Asian Pac J Cancer Prev; 2022 Jun; 23(6):2137-2143. PubMed ID: 35763658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial.
    Clemmons AB; Orr J; Andrick B; Gandhi A; Sportes C; DeRemer D
    Biol Blood Marrow Transplant; 2018 Oct; 24(10):2065-2071. PubMed ID: 29906570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olanzapine with ondansetron and dexamethasone for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in lung cancer.
    Wang W; Lou G; Zhang Y
    Medicine (Baltimore); 2018 Sep; 97(37):e12331. PubMed ID: 30212982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.